Literature DB >> 11454527

Multivariate analysis of factors influencing quality of life and utility in patients with haemophilia.

S Trippoli1, M Vaiani, S Linari, G Longo, M Morfini, A Messori.   

Abstract

BACKGROUND AND OBJECTIVES: Although several studies have determined quality of life (QOL) in patients with hemophilia, generic questionnaires have rarely been used. The objectives of our study were; 1) to measure QOL and utility in patients with hemophilia using the Short Form 36 (SF-36) and the EuroQOL questionnaires; 2) to evaluate the influence of some clinical variables on QOL and utility; 3) to assess the correlation between the two questionnaires. DESIGN AND METHODS: All consecutive patients with hemophilia were asked to complete the SF-36 and the EuroQOL questionnaires. The following information was recorded from each patient: age, type of hemophilia, severity of disease, HCV and HIV infection, number of bleeding episodes and cumulative dose of coagulation factors over the previous year. These items were entered into a multivariate analysis to assess their effect on QOL. Correlation analyses were conducted to evaluate the relationship between the EuroQOL and SF-36.
RESULTS: Fifty-six patients completed the SF-36 and the EuroQOL questionnaires. The mean scores of the SF-36 ranged from 55.2 (general health) to 74.7 (social functioning). The EuroQOLself-classifier and the EuroQOLvas showed a mean score of 0.67 (SD=0.26) and 0.66 (SD=0.17), respectively. Among the clinical variables, age significantly influenced both the EuroQOL and the SF-36 scores. The EuroQOL indices showed a statistically significant correlation with each dimension of the SF-36. INTERPRETATION AND
CONCLUSIONS: Our study quantified the degree to which QOL is impaired in patients with hemophilia by using both a generic questionnaire and a utility-based approach.

Entities:  

Mesh:

Year:  2001        PMID: 11454527

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  7 in total

Review 1.  Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis.

Authors:  Scott D Grosse; Shraddha S Chaugule; Joel W Hay
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015-01-14       Impact factor: 2.217

2.  Health-related quality of life in a rare disease: hereditary hemorrhagic telangiectasia (HHT) or Rendu-Osler-Weber disease.

Authors:  Giovanna Pasculli; Francesco Resta; Edoardo Guastamacchia; Leonardo Di Gennaro; Patrizia Suppressa; Carlo Sabbà
Journal:  Qual Life Res       Date:  2004-12       Impact factor: 4.147

3.  Assessing quality of life in individuals with hereditary blood coagulation disorders.

Authors:  S Solovieva; N Santavirta; S Santavirta; Y T Konttinen
Journal:  Qual Life Res       Date:  2004-06       Impact factor: 4.147

4.  Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries.

Authors:  Ernesto Cimino; Silvia Linari; Mara Malerba; Susan Halimeh; Francesca Biondo; Martina Westfeld
Journal:  Patient Prefer Adherence       Date:  2014-12-12       Impact factor: 2.711

5.  Psychometric properties of the Greek Haem-A-QoL for measuring quality of life in Greek haemophilia patients.

Authors:  Agoritsa Varaklioti; Nick Kontodimopoulos; Olga Katsarou; Dimitris Niakas
Journal:  Biomed Res Int       Date:  2014-05-06       Impact factor: 3.411

6.  Health-Related Quality of Life and Association With Arthropathy in Greek Patients with Hemophilia.

Authors:  Agoritsa Varaklioti; Nick Kontodimopoulos; Dimitris Niakas; Anna Kouramba; Olga Katsarou
Journal:  Clin Appl Thromb Hemost       Date:  2017-10-09       Impact factor: 2.389

Review 7.  Patient-reported outcomes in autosomal inherited bleeding disorders: A systematic literature review.

Authors:  Evelien S van Hoorn; Maite E Houwing; Wala Al Arashi; Frank W G Leebeek; Jan A Hazelzet; Samantha C Gouw; Roger E G Schutgens; Saskia E M Schols; Hester F Lingsma; Marjon H Cnossen
Journal:  Haemophilia       Date:  2022-01-18       Impact factor: 4.263

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.